Stifel Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $156

Stifel analyst James Condulis has reiterated a Buy rating on Mirum Pharmaceuticals (NASDAQ: MIRM) and increased the price target from $136 to $156. This adjustment reflects a positive outlook on the company's performance.